These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 3653231)

  • 1. Pharmacokinetics and systemic availability of the antihypertensive agent indoramin and its metabolite 6-hydroxyindoramin in healthy subjects.
    Pierce DM; Abrams SM; Franklin RA
    Eur J Clin Pharmacol; 1987; 32(6):619-23. PubMed ID: 3653231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intra- and inter-subject variation in the pharmacokinetics of indoramin and its 6-hydroxylated metabolite.
    Pierce DM; Abrams SM; Franklin RA
    Eur J Clin Pharmacol; 1988; 35(2):195-8. PubMed ID: 3191938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of indoramin and its 6-hydroxylated metabolite after repeated oral dosing.
    Pierce DM; Warrington SJ; Franklin RA
    Biopharm Drug Dispos; 1988; 9(2):147-57. PubMed ID: 2897212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pharmacokinetics of oral indoramin during pregnancy.
    Schabort I; Odendaal HJ; Pierce DM
    Br J Clin Pharmacol; 1990 Apr; 29(4):397-401. PubMed ID: 2328193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of indoramin and its metabolite 6-hydroxyindoramin after single and multiple doses to cirrhotic liver patients.
    Neumann G; Wilke G; Reimold WV; Pierce DM; Giesing M
    J Cardiovasc Pharmacol; 1986; 8 Suppl 2():S20-4. PubMed ID: 2423791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pharmacokinetics of indoramin and 6-hydroxyindoramin in poor and extensive hydroxylators of debrisoquine.
    Pierce DM; Smith SE; Franklin RA
    Eur J Clin Pharmacol; 1987; 33(1):59-65. PubMed ID: 3691597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of the clinical pharmacokinetics and metabolism of the alpha 1-adrenoceptor antagonist indoramin.
    Pierce DM
    Xenobiotica; 1990 Dec; 20(12):1357-67. PubMed ID: 1981634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic interaction between indoramin and ethanol.
    Abrams SM; Pierce DM; Johnston A; Hedges A; Franklin RA; Turner P
    Hum Toxicol; 1989 May; 8(3):237-41. PubMed ID: 2744781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of oral indoramin in elderly and middle-aged female volunteers.
    Norbury HM; Franklin RA; Marrott PK; Warrington SJ
    Eur J Clin Pharmacol; 1984; 27(2):247-9. PubMed ID: 6499905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent developments in the pharmacology and pharmacokinetics of indoramin.
    Archibald JL
    J Cardiovasc Pharmacol; 1986; 8 Suppl 2():S16-9. PubMed ID: 2423790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of indoramin in man.
    Draffan GH; Lewis PJ; Firmin JL; Jordan TW; Dollery CT
    Br J Clin Pharmacol; 1976 Jun; 3(3):489-95. PubMed ID: 788751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of intravenous indoramin in middle-aged male and female volunteers.
    Norbury HM; Franklin RA; Marrott PK; Warrington SJ
    Eur J Clin Pharmacol; 1983; 25(2):243-6. PubMed ID: 6628508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of oral indoramin.
    Volans GN; Jeffereys D; Latham AN; Frost T
    Curr Med Res Opin; 1982; 8(1):51-3. PubMed ID: 7105823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cefetamet pivoxil clinical pharmacokinetics.
    Blouin RA; Stoeckel K
    Clin Pharmacokinet; 1993 Sep; 25(3):172-88. PubMed ID: 8222459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of hydroxy-3(S)-dihydroquinidine in healthy volunteers after intravenous and oral administration.
    Jaillon P; Poirier JM; Lecocq B; Jarreau C; Pays M; Richard MO; Cheymol G
    Eur J Drug Metab Pharmacokinet; 1986; 11(3):233-8. PubMed ID: 3816879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the pharmacokinetics of dolasetron and its major active metabolite, reduced dolasetron, in dog.
    Dow J; Francesco GF; Berg C
    J Pharm Sci; 1996 Jul; 85(7):685-9. PubMed ID: 8818990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetics of clofarabine and its metabolite 6-ketoclofarabine in adult and pediatric patients with cancer.
    Bonate PL; Cunningham CC; Gaynon P; Jeha S; Kadota R; Lam GN; Razzouk B; Rytting M; Steinherz P; Weitman S
    Cancer Chemother Pharmacol; 2011 Apr; 67(4):875-90. PubMed ID: 20582417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and absolute bioavailability of salbutamol in healthy adult volunteers.
    Goldstein DA; Tan YK; Soldin SJ
    Eur J Clin Pharmacol; 1987; 32(6):631-4. PubMed ID: 3653233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Studies on the metabolism of the new anti-hypertensive agent, indoramin, in man.
    Franklin RA; Robson P; Stevenson D
    Eur J Clin Pharmacol; 1983; 24(5):629-34. PubMed ID: 6873141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.